

Publicazioni

Prof. Riccardo Valdagni

1. Gandellini P, Casiraghi N, Rancati T, Benelli M, Doldi V, Romanel A, Colecchia M, Marengi C, **Valdagni R**, Demichelis F, Zaffaroni N. Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations. *Eur Urol Oncol*. 2019 May;2(3):277-285. doi: 10.1016/j.euo.2018.08.010. Epub 2018 Sep 10. PubMed PMID: 31200842.
2. Seibold P, Webb A, Aguado-Barrera ME, Azria D, Bourcier C, Brengues M, Briers E, Bultijnck R, Calvo-Crespo P, Carballo A, Choudhury A, Cicchetti A, Claßen J, Delmastro E, Dunning AM, Elliott RM, Farcy-Jacquet MP, Gabriele P, Garibaldi E, Gómez-Caamaño A, Gutiérrez-Enríquez S, Higginson DS, Johnson K, Lobato-Busto R, Mollà M, Müller A, Payne D, Peleteiro P, Post G, Rancati T, Rattay T, Reyes V, Rosenstein BS, De Ruyscher D, De Santis MC, Schäfer J, Schnabel T, Sperk E, Symonds RP, Stobart H, Taboada-Valladares B, Talbot CJ, **Valdagni R**, Vega A, Veldeman L, Ward T, Weißenberger C, West CML, Chang-Claude J; REQUITE consortium. REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. *Radiother Oncol*. 2019 May 27;138:59-67. doi: 10.1016/j.radonc.2019.04.034. [Epub ahead of print] PubMed PMID: 31146072.
3. La Rocca E, Lici V, Giandini T, Bonfantini F, Frasca S, Dispinzieri M, Gennaro M, S DC, Di Cosimo S, Lozza L, Pignoli E, **Valdagni R**, De Santis MC. Interobserver variability (between radiation oncologist and radiation therapist) in tumor bed contouring after breast-conserving surgery. *Tumori*. 2019 Jun;105(3):210-215. doi:10.1177/0300891619839288. Epub 2019 Mar 27. PubMed PMID: 30915903.
4. Wirth M, Fossati N, Albers P, Bangma C, Brausi M, Comperat E, Faithfull S, Gillissen S, Jereczek-Fossa BA, Mastris K, Mottet N, Müller SC, Pieters B, Ribal MJ, Sangar V, Schoots IG, Smelov V, Travado L, **Valdagni R**, Wesselmann S, Wiegel T, van Poppel H. The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. *Eur Urol*. 2019 Feb 21. pii: S0302-2838(19)30077-6. doi:10.1016/j.eururo.2019.01.033. [Epub ahead of print] PubMed PMID: 30799188.
5. Menichetti J, De Luca L, Dordoni P, Donegani S, Marengi C, **Valdagni R**, Bellardita L. Making Active Surveillance a path towards health promotion: A qualitative study on prostate cancer patients' perceptions of health promotion during Active Surveillance. *Eur J Cancer Care (Engl)*. 2019 May;28(3):e13014. doi:10.1111/ecc.13014. Epub 2019 Feb 13. PubMed PMID: 30761643.
6. Cicchetti A, Fiorino C, Rancati T, **Valdagni R**. In Reply to Loganadane et al. *Int J Radiat Oncol Biol Phys*. 2019 Mar 1;103(3):777-778. doi:10.1016/j.ijrobp.2018.11.001. PubMed PMID: 30722974.
7. El Bezawy R, Tinelli S, Tortoreto M, Doldi V, Zuco V, Folini M, Stucchi C, Rancati T, **Valdagni R**, Gandellini P, Zaffaroni N. miR-205 enhances radiation sensitivity of prostate cancer cells by impairing DNA damage repair through PKC ϵ and ZEB1 inhibition. *J Exp Clin Cancer Res*. 2019 Feb 4;38(1):51. doi:10.1186/s13046-019-1060-z. PubMed PMID: 30717752; PubMed Central PMCID: PMC6360656.
8. Profumo V, Forte B, Percio S, Rotundo F, Doldi V, Ferrari E, Fenderico N, Dugo M, Romagnoli D, Benelli M, **Valdagni R**, Dolfini D, Zaffaroni N, Gandellini P. LEADeR role of miR-205 host gene as long noncoding RNA in prostate basal cell differentiation. *Nat Commun*. 2019 Jan 18;10(1):307. doi:10.1038/s41467-018-08153-2. PubMed PMID: 30659180; PubMed Central PMCID: PMC6338800.
9. Dizdarevic S, Petersen PM, Essler M, Versari A, Bourre JC, la Fougère C, **Valdagni R**, Paganelli G, Ezziddin S, Kalinovsky J, Bayh I, Du Y. Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC population for long-term Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice. *Eur J Nucl Med Mol Imaging*. 2019 May;46(5):1102-1110. doi: 10.1007/s00259-019-4261-y. Epub 2019 Jan 12. PubMed PMID: 30637501; PubMed Central PMCID: PMC6451709.
10. Jereczek-Fossa BA, Bortolato B, Gerardi MA, Dicuonzo S, Arienti VM, Berlinghieri S, Bracelli S, Buglione M, Caputo M, Catalano G, Cazzaniga LF, DeCicco L, Di Muzio N, Filippone FR, Fodor A, Franceschini D, Frata P, Gottardo S, Ivaldi GB, Laudati A, Magrini SM, Mantero E, Meaglia I, Morlino S, Palazzi M, Piccoli F, Romanelli P, Scorsetti M, Serafini F, Scandolaro L, **Valdagni R**, Orecchia R, Antognoni P; Lombardy Section of the Italian Society of Oncological Radiotherapy (Associazione Italiana di Radioterapia Oncologica-Lombardia, AIRO-L). Radiotherapy for

oligometastatic cancer: a survey among radiation oncologists of Lombardy (AIRO-Lombardy), Italy. *Radiol Med*. 2019 Apr;124(4):315-322. doi: 10.1007/s11547-018-0972-6. Epub 2018 Dec 15. PubMed PMID: 30554376.

11. La Rocca E, Dispinzieri M, Lozza L, Mariani G, Di Cosimo S, Gennaro M, **Valdagni R**, De Santis MC. Radiotherapy with the anti-programmed cell death ligand-1 immune checkpoint blocker avelumab: acute toxicities in triple-negative breast cancer. *Med Oncol*. 2018 Nov 15;36(1):4. doi: 10.1007/s12032-018-1228-y. PubMed PMID: 30443687.
12. Orlandi E, Iacovelli NA, Rancati T, Cicchetti A, Bossi P, Pignoli E, Bergamini C, Licitra L, Fallai C, **Valdagni R**, Cavallo A. Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients. *Oral Oncol*. 2018 Nov;86:266-272. doi:10.1016/j.oraloncology.2018.10.006. Epub 2018 Oct 11. PubMed PMID: 30409311.
13. Johnson K, Chang-Claude J, Critchley AM, Kyriacou C, Lavers S, Rattay T, Seibold P, Webb A, West C, Symonds RP, Talbot CJ; REQUITE Consortium. Genetic Variants Predict Optimal Timing of Radiotherapy to Reduce Side-effects in Breast Cancer Patients. *Clin Oncol (R Coll Radiol)*. 2019 Jan;31(1):9-16. doi:10.1016/j.clon.2018.10.001. Epub 2018 Oct 30. PubMed PMID: 30389261.
14. Van Hemelrijck M, Ji X, Helleman J, Roobol MJ, van der Linden W, Nieboer D, Bangma CH, Frydenberg M, Rannikko A, Lee LS, Gnanapragasam VJ, Kattan MW; Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium; Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium. Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. *Eur Urol*. 2019 Mar;75(3):523-531. doi:10.1016/j.eururo.2018.10.025. Epub 2018 Oct 29. PubMed PMID: 30385049.
15. Grisotto S, Cerrotta A, Pappalardi B, Carrara M, Messina A, Tenconi C, **Valdagni R**, Fallai C. Pre-implant magnetic resonance and transrectal ultrasound imaging in high-dose-rate prostate brachytherapy: comparison of prostate volumes, craniocaudal extents, and contours. *J Contemp Brachytherapy*. 2018 Aug;10(4):285-290. doi: 10.5114/jcb.2018.77947. Epub 2018 Aug 31. PubMed PMID: 30237811; PubMed Central PMCID: PMC6142648.
16. Carrara M, Massari E, Cicchetti A, Giandini T, Avuzzi B, Palorini F, Stucchi C, Fellin G, Gabriele P, Vavassori V, Degli Esposti C, Cozzarini C, Pignoli E, Fiorino C, Rancati T, **Valdagni R**. Development of a Ready-to-Use Graphical Tool Based on Artificial Neural Network Classification: Application for the Prediction of Late Fecal Incontinence After Prostate Cancer Radiation Therapy. *Int J Radiat Oncol Biol Phys*. 2018 Dec 1;102(5):1533-1542. doi: 10.1016/j.ijrobp.2018.07.2014. Epub 2018 Aug 6. PubMed PMID: 30092335.
17. Palazzi MF, Soatti C, Jereczek-Fossa BA, Cazzaniga LF, Antognoni P, Gardani G, Amadori M, Baio A, Beltramo G, Bignardi M, Bracelli S, Buffoli A, Castiglioni S, Catalano G, Di Muzio N, Fallai C, Fariselli L, Frata P, Gramaglia A, Italia C, Ivaldi G, Lombardi F, Magrini SM, Nava S, Sarti E, Scandolaro L, Scorsetti M, Stiglich F, Tortini R, **Valdagni R**, Valvo F, Vavassori V, Sbicego EL, Tonoli S, Orecchia R. Equipment, staffing, and provision of radiotherapy in Lombardy, Italy: Results of three surveys performed between 2012 and 2016. *Tumori*. 2018 Oct;104(5):352-360. doi: 10.1177/0300891618784800. Epub 2018 Jul 9. PubMed PMID: 29986637.
18. Magnani T, Bracarda S, D'Angelillo RM, Artibani W, Barni S, Beretta G, Brausi M, Caffo O, Corvò R, Gallucci M, Gunelli R, Mirone V, Novara G, Pinto C, Russi E, Santoni R, Tomirotti M, Volpe A, Conti G, **Valdagni R**. Multidisciplinary teams for the proper management of patients with genitourinary tumors: When topics set scientific societies' agenda. *Tumori*. 2019 Apr;105(2):161-167. doi:10.1177/0300891618784789. Epub 2018 Jul 5. PubMed PMID: 29974825.
19. Cicchetti A, Avuzzi B, Palorini F, Ballarini F, Stucchi C, Fellin G, Gabriele P, Vavassori V, Esposti CD, Cozzarini C, Fiorino C, Rancati T, **Valdagni R**. Predicting Late Fecal Incontinence Risk After Radiation Therapy for Prostate Cancer: New Insights From External Independent Validation. *Int J Radiat Oncol Biol Phys*. 2018 Sep 1;102(1):127-136. doi: 10.1016/j.ijrobp.2018.05.013. Epub 2018 Jun 30. PubMed PMID: 29970313.
20. Dispinzieri M, La Rocca E, Meneghini E, Fiorentino A, Lozza L, Di Cosimo S, Gennaro M, Cosentino V, Sant M, Pignoli E, **Valdagni R**, Bonfantini F, De Santis MC. Discontinuation of hormone therapy for elderly breast cancer patients after hypofractionated whole-breast radiotherapy. *Med Oncol*. 2018 Jun 16;35(7):107. doi: 10.1007/s12032-018-1165-9. PubMed PMID: 29907919.
21. Porreca A, Noale M, Artibani W, Bassi PF, Bertoni F, Bracarda S, Conti GN, Corvò R, Gacci M, Graziotti P, Magrini SM, Mirone V, Montironi R, Muto G, Pecoraro S, Ricardi U, Russi E, Tubaro A, Zagonel V, Crepaldi G, Maggi S;

- Pros-ITCNR study group. Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study. *Health Qual Life Outcomes*. 2018 Jun 13;16(1):122. doi: 10.1186/s12955-018-0952-5. PubMed PMID: 29898750; PubMed Central PMCID: PMC6001046.
22. De Santis MC, Bonfantini F, Di Salvo F, Fiorentino A, Dispinzieri M, Caputo M, Di Cosimo S, Mariani G, Gennaro M, Cosentino V, Sant M, Pignoli E, **Valdagni R**, Lozza L. Hypofractionated Whole-Breast Irradiation With or Without Boost in Elderly Patients: Clinical Evaluation of an Italian Experience. *Clin Breast Cancer*. 2018 Oct;18(5):e1059-e1066. doi: 10.1016/j.clbc.2018.04.003. Epub 2018 Apr 22. PubMed PMID: 29773414.
23. Bedini N, Cicchetti A, Palorini F, Magnani T, Zuco V, Pennati M, Campi E, Allavena P, Pesce S, Villa S, Avuzzi B, Morlino S, Visentin ME, Zaffaroni N, Rancati T, **Valdagni R**. Evaluation of Mediators Associated with the Inflammatory Response in Prostate Cancer Patients Undergoing Radiotherapy. *Dis Markers*. 2018 Feb 25;2018:9128128. doi: 10.1155/2018/9128128. eCollection 2018. PubMed PMID: 29682101; PubMed Central PMCID: PMC5845513.
24. Menichetti J, **Valdagni R**, Bellardita L. Quality of life in active surveillance and the associations with decision-making—a literature review. *Transl Androl Urol*. 2018 Feb;7(1):160-169. doi: 10.21037/tau.2017.12.34. Review. PubMed PMID: 29594030; PubMed Central PMCID: PMC5861287.
25. Drost FH, Rannikko A, **Valdagni R**, Pickles T, Kakehi Y, Remmers S, van der Poel HG, Bangma CH, Roobol MJ; PRIAS study group. Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study. *Transl Androl Urol*. 2018 Feb;7(1):98-105. doi: 10.21037/tau.2017.12.28. PubMed PMID: 29594024; PubMed Central PMCID: PMC5861273.
26. Scalco E, Rancati T, Pirovano I, Mastropietro A, Palorini F, Cicchetti A, Messina A, Avuzzi B, **Valdagni R**, Rizzo G. Texture analysis of T1-w and T2-w MR images allows a quantitative evaluation of radiation-induced changes of internal obturator muscles after radiotherapy for prostate cancer. *Med Phys*. 2018 Apr;45(4):1518-1528. doi: 10.1002/mp.12798. Epub 2018 Feb 26. PubMed PMID: 29415344.
27. Bruinsma SM, Zhang L, Roobol MJ, Bangma CH, Steyerberg EW, Nieboer D, Van Hemelrijck M; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium. The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date. *BJU Int*. 2018 May;121(5):737-744. doi: 10.1111/bju.14106. Epub 2018 Jan 18. PubMed PMID: 29247473.
28. De Santis MC, Bonfantini F, Di Salvo F, Fiorentino A, Riboldi VM, Di Cosimo S, Bianchi GV, Gennaro M, Cosentino V, Sant M, Pignoli E, **Valdagni R**, Lozza L. Trastuzumab and Hypofractionated Whole Breast Radiotherapy: A Victorious Combination? *Clin Breast Cancer*. 2018 Jun;18(3):e363-e371. doi: 10.1016/j.clbc.2017.08.011. Epub 2017 Aug 24. PubMed PMID: 28958838.
29. Rancati T, Palorini F, Cozzarini C, Fiorino C, **Valdagni R**. Understanding urinary toxicity after radiotherapy for prostate cancer: first steps forward. *Tumori*. 2017 Sep 18;103(5):395-404. doi: 10.5301/tj.5000681. Epub 2017 Sep 7. Review. PubMed PMID: 28885678.
30. Cozzarini C, Rancati T, Palorini F, Avuzzi B, Garibaldi E, Balestrini D, Cante D, Munoz F, Franco P, Girelli G, Sini C, Vavassori V, **Valdagni R**, Fiorino C. Patient-reported urinary incontinence after radiotherapy for prostate cancer: Quantifying the dose-effect. *Radiother Oncol*. 2017 Oct;125(1):101-106. doi: 10.1016/j.radonc.2017.07.029. Epub 2017 Aug 18. PubMed PMID: 28826629.
31. Sini C, Noris Chiorda B, Gabriele P, Sanguineti G, Morlino S, Badenchini F, Cante D, Carillo V, Gaetano M, Giandini T, Landoni V, Maggio A, Perna L, Petrucci E, Sacco V, **Valdagni R**, Rancati T, Fiorino C, Cozzarini C. Patient-reported intestinal toxicity from whole pelvis intensity-modulated radiotherapy: First quantification of bowel dose-volume effects. *Radiother Oncol*. 2017 Aug;124(2):296-301. doi: 10.1016/j.radonc.2017.07.005. Epub 2017 Jul 21. PubMed PMID: 28739383.
32. Giandini T, Tenconi C, Carrara M, Ciocca M, Russo S, Panaino CMV, Cattani F, Ciardo D, Morlino S, Avuzzi B, Bedini N, Villa S, Marvaso G, Romanelli P, Hasegawa A, Vischioni B, Valvo F, Jereczek-Fossa BA, Orecchia R, **Valdagni R**, Pignoli E. Physicists' views on hadrontherapy: a survey of members of the Italian Association of Medical Physics (AIFM). *Tumori*. 2017 Sep 18;103(5):430-437. doi: 10.5301/tj.5000654. Epub 2017 Jul 8. PubMed PMID: 28708234.
33. Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli

RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, **Valdagni R**, Wiegel T, Omlin A. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC2017. *Eur Urol*. 2018 Feb;73(2):178-211. doi: 10.1016/j.eururo.2017.06.002. Epub 2017 Jun 24. PubMed PMID: 28655541.

34. Marengi C, Alvisi MF, Palorini F, Avuzzi B, Badenchini F, Bedini N, Bellardita L, BIASONI D, Bosetti D, Casale A, Catanzaro M, Colecchia M, De Luca L, Donegani S, Dordoni P, Lanocita R, Maffezzini M, Magnani T, Menichetti J, Messina A, Morlino S, Paolini B, Rancati T, Stagni S, Tesone A, Torelli T, Tulli Baldoïn E, Vaiani M, Villa S, Villa S, Zaffaroni N, Nicolai N, Salvioni R, **Valdagni R**. Eleven-year management of prostate cancer patients on active surveillance: what have we learned? *Tumori*. 2017 Sep 18;103(5):464-474. doi:10.5301/tj.5000649. Epub 2017 Jun 14. PubMed PMID: 28623636; PubMed Central PMCID: PMC6379800.

35. Alvisi MF, Repetto C, Rancati T, Badenchini F, Magnani T, Marengi C, Villa S, Nicolai N, Salvioni R, Avuzzi B, **Valdagni R**, Bellardita L; Prostate Cancer Multidisciplinary Clinic Working Group. Italian cultural adaptation of the Memorial Anxiety for Prostate Cancer scale for the population of men on active surveillance. *Tumori*. 2018 Jun;104(3):172-178. doi: 10.5301/tj.5000646. Epub 2018 May 9. PubMed PMID: 28623635.

36. Baldari S, Boni G, Bortolus R, Caffo O, Conti G, De Vincentis G, Monari F, Procopio G, Santini D, Seregni E, **Valdagni R**. Management of metastatic castration-resistant prostate cancer: A focus on radium-223: Opinions and suggestions from an expert multidisciplinary panel. *Crit Rev Oncol Hematol*. 2017 May;113:43-51. doi: 10.1016/j.critrevonc.2017.03.001. Epub 2017 Mar 6. Review. PubMed PMID: 28427521.

37. Monfardini S, Morlino S, **Valdagni R**, Catanzaro M, Tafa A, Bortolato B, Petralia G, Bonetto E, Villa E, Picozzi S, Locatelli MC, Galetti G, Millul A, Albanese Y, Bianchi E, Panzarino C, Gerardi F, Beghi E. Follow-up of elderly patients with urogenital cancers: Evaluation of geriatric care needs and related actions. *J Geriatr Oncol*. 2017 Jul;8(4):289-295. doi: 10.1016/j.jgo.2017.02.011. Epub 2017 Mar 11. PubMed PMID: 28292646.

38. Vicentini M, Sacchetti C, Trama A, Nicolai N, Gatta G, Botta L, **Valdagni R**, Giorgi Rossi P; Prostate Cancer High-Resolution Study Working Group. Changes in mortality and incidence of prostate cancer by risk class in different periods in Italy: the possible effects of PSA spread. *Tumori*. 2017 May 12;103(3):292-298. doi: 10.5301/tj.5000613. Epub 2017 Feb 28. PubMed PMID: 28291906.

39. Bruinsma SM, Roobol MJ, Carroll PR, Klotz L, Pickles T, Moore CM, Gnanapragasam VJ, Villers A, Rannikko A, **Valdagni R**, Frydenberg M, Kakehi Y, Filson CP, Bangma CH; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium. Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure. *Nat Rev Urol*. 2017 May;14(5):312-322. doi:10.1038/nrurol.2017.26. Epub 2017 Mar 14. Review. PubMed PMID: 28290462.

40. El Bezawy R, Cominetti D, Fenderico N, Zuco V, Beretta GL, Dugo M, Arrighetti N, Stucchi C, Rancati T, **Valdagni R**, Zaffaroni N, Gandellini P. miR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis. *Cancer Lett*. 2017 Jun 1;395:53-62. doi: 10.1016/j.canlet.2017.02.033. Epub 2017 Mar 6. PubMed PMID: 28274892.

41. Noale M, Maggi S, Artibani W, Bassi PF, Bertoni F, Bracarda S, Conti GN, Corvò R, Gacci M, Graziotti P, Magrini SM, Maurizi Enrici R, Mirone V, Montironi R, Muto G, Pecoraro S, Porreca A, Ricardi U, Tubaro A, Zagonel V, Zattoni F, Crepaldi G; Pros-IT CNR study group. Pros-IT CNR: an Italian prostate cancer monitoring project. *Aging Clin Exp Res*. 2017 Apr;29(2):165-172. doi:10.1007/s40520-017-0735-6. Epub 2017 Feb 24. PubMed PMID: 28236267.

42. Giandini T, Panaino CM, Avuzzi B, Morlino S, Villa S, Bedini N, Carabelli G, Frasca SC, Romanyukha A, Rosenfeld A, Pignoli E, **Valdagni R**, Carrara M. An accurate method to quantify breathing-induced prostate motion for patients implanted with electromagnetic transponders. *Tumori*. 2017 Mar 24;103(2):136-142. doi: 10.5301/tj.5000609. Epub 2017 Feb 11. PubMed PMID: 28218381.

43. Frigerio B, Franssen G, Luison E, Satta A, Seregni E, Colombatti M, Fracasso G, **Valdagni R**, Mezzananza D, Boerman O, Canevari S, Figini M. Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging. *Oncotarget*. 2017 Feb 14;8(7):10919-10930. doi:10.18632/oncotarget.14229. PubMed PMID: 28051996; PubMed Central PMCID: PMC5355234.

44. Marvaso G, Jereczek-Fossa BA, Vischioni B, Ciardo D, Giandini T, Hasegawa A, Cattani F, Carrara M, Ciocca M, Bedini N, Villa S, Morlino S, Russo S, Zerini D, Colangione SP, Panaino CMV, Fodor C, Santoro L, Pignoli E, Valvo F,

- Valdagni R, De Cobelli O, Orecchia R.** Phase II multi-institutional clinical trial on a new mixed beam RT scheme of IMRT on pelvis combined with a carbon ion boost for high-risk prostate cancer patients. *Tumori*. 2017 May 12;103(3):314-318. doi:10.5301/tj.5000587. Epub 2016 Dec 2. PubMed PMID: 28009421.
45. Menichetti J, Villa S, Magnani T, Avuzzi B, Bosetti D, Marengi C, Morlino S, Rancati T, Van Poppel H, Salvioni R, **Valdagni R**, Bellardita L. Lifestyle interventions to improve the quality of life of men with prostate cancer: A systematic review of randomized controlled trials. *Crit Rev Oncol Hematol*. 2016 Dec;108:13-22. doi: 10.1016/j.critrevonc.2016.10.007. Epub 2016 Oct 20. Review. PubMed PMID: 27931831.
46. Repetto C, Rancati T, Magnani T, Alvisi MF, Avuzzi B, Badenchini F, Marengi C, Stagni S, Maffezzini M, Villa S, Villa S, Salvioni R, **Valdagni R**, Bellardita L. "What if...": decisional regret in patients who discontinued active surveillance. *Tumori*. 2016 Dec 1;102(6):562-568. doi: 10.5301/tj.5000564. Epub 2016 Sep 22. PubMed PMID: 27716881.
47. Marvaso G, Vischioni B, Jereczek-Fossa BA, Ciardo D, Fossati P, Giandini T, Morlino S, Carrara M, Romanelli P, Russi E, Valvo F, **Valdagni R**, Orecchia R. Hadrontherapy from the Italian Radiation Oncologist point of view: face the reality. The Italian Society of Oncological Radiotherapy (AIRO) survey. *Radiol Med*. 2017 Feb;122(2):140-145. doi: 10.1007/s11547-016-0699-1. Epub 2016 Oct 21. PubMed PMID: 27770265.
48. Cicchetti A, Rancati T, Ebert M, Fiorino C, Palorini F, Kennedy A, Joseph DJ, Denham JW, Vavassori V, Fellin G, Avuzzi B, Stucchi C, **Valdagni R**. Modelling late stool frequency and rectal pain after radical radiotherapy in prostate cancer patients: Results from a large pooled population. *Phys Med*. 2016 Dec;32(12):1690-1697. doi: 10.1016/j.ejmp.2016.09.018. Epub 2016 Oct 6. PubMed PMID: 27720692.
49. Villa S, Kendel F, Venderbos L, Rancati T, Bangma C, Carroll P, Denis L, Klotz L, Korfage IJ, Lane AJ, Magnani T, Mastris K, Rannikko A, Roobol M, Trock B, Van den Bergh R, Van Poppel H, **Valdagni R**, Bellardita L. Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force. *Eur Urol*. 2017 Feb;71(2):274-280. doi: 10.1016/j.eururo.2016.09.041. Epub 2016 Oct 6. PubMed PMID: 27720532.
50. Trama A, Botta L, Nicolai N, Rossi PG, Contiero P, Fusco M, Lodde M, Pannozzo F, Piffer S, Puppo A, Seeber A, Tumino R, **Valdagni R**, Gatta G; Prostate Cancer High Resolution Study Working Group. Prostate cancer changes in clinical presentation and treatments in two decades: an Italian population-based study. *Eur J Cancer*. 2016 Nov;67:91-98. doi: 10.1016/j.ejca.2016.07.021. Epub 2016 Sep 10. PubMed PMID: 27620947.
51. **Valdagni R**. Multidisciplinary Team Meetings in Cancer Care: We Could and Should do Better Than This. *Clin Oncol (R Coll Radiol)*. 2016 Dec;28(12):799-800. doi: 10.1016/j.clon.2016.08.015. Epub 2016 Sep 9. PubMed PMID: 27618423.
52. Verzoni E, Grassi P, Ratta R, Nigam M, De Braud F, **Valdagni R**, Procopio G. Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors. *Ther Adv Med Oncol*. 2016 Sep;8(5):323-30. doi: 10.1177/1758834016656493. Epub 2016 Jul 5. PubMed PMID: 27583024; PubMed Central PMCID: PMC4981293.
53. Improta I, Palorini F, Cozzarini C, Rancati T, Avuzzi B, Franco P, Degli Esposti C, Del Mastro E, Girelli G, Iotti C, Vavassori V, **Valdagni R**, Fiorino C. Bladder spatial-dose descriptors correlate with acute urinary toxicity after radiation therapy for prostate cancer. *Phys Med*. 2016 Dec;32(12):1681-1689. doi: 10.1016/j.ejmp.2016.08.013. Epub 2016 Aug 25. PubMed PMID: 27570122.
54. De Santis MC, Bonfantini F, Di Salvo F, Dispinzieri M, Mantero E, Soncini F, Baili P, Sant M, Bianchi G, Maggi C, Di Cosimo S, Agresti R, Pignoli E, **Valdagni R**, Lozza L. Factors influencing acute and late toxicity in the era of adjuvant hypofractionated breast radiotherapy. *Breast*. 2016 Oct;29:90-5. doi: 10.1016/j.breast.2016.07.013. Epub 2016 Jul 29. PubMed PMID: 27476083.
55. Bellardita L, Damiano R, Porpiglia F, Scattoni V, Amodeo A, Bortolus R, Lapini A, Cocci A, Cicalese V, Caponera M, Mastrangelo P, Francesca F, **Valdagni R**, Taverna G, di Trapani D, Leonardi R, Minocci D, Gaboardi F, Montanari E, Conti G. Adaptation and validation of an Italian version of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI). *Eur Rev Med Pharmacol Sci*. 2016 Jul;20(13):2773-8. PubMed PMID: 27424974.
56. Moore CM, Giganti F, Albertsen P, Allen C, Bangma C, Briganti A, Carroll P, Haider M, Kasivisvanathan V, Kirkham A, Klotz L, Ouzzane A, Padhani AR, Panebianco V, Pinto P, Puech P, Rannikko A, Renard-Penna R, Touijer K,

Turkbey B, van Poppel H, **Valdagni R**, Walz J, Schoots I. Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force. *Eur Urol.* 2017Apr;71(4):648-655. doi: 10.1016/j.eururo.2016.06.011. Epub 2016 Jun 24. PubMed PMID: 27349615.

57. Bokhorst LP, **Valdagni R**, Rannikko A, Kakehi Y, Pickles T, Bangma CH, Roobol MJ; PRIAS study group. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment. *Eur Urol.* 2016 Dec;70(6):954-960. doi: 10.1016/j.eururo.2016.06.007. Epub 2016 Jun 19. PubMed PMID: 27329565.

58. Carrara M, Giandini T, Pariani C, Pignoli E, Rancati T, **Valdagni R**, De Santis C, Lozza L. Comment on "Objective assessment in digital images of skin erythema caused by radiotherapy" [*Med. Phys.* 42, 5568-5577 (2015)]. *Med Phys.* 2016May;43(5):2687. doi: 10.1118/1.4945019. PubMed PMID: 27147377.

59. Cozzarini C, Rancati T, Badenchini F, Palorini F, Avuzzi B, Degli Esposti C, Girelli G, Improta I, Vavassori V, **Valdagni R**, Fiorino C. Baseline status and dose to the penile bulb predict impotence 1 year after radiotherapy for prostate cancer. *Strahlenther Onkol.* 2016 May;192(5):297-304. doi:10.1007/s00066-016-0964-1. Epub 2016 Apr 14. PubMed PMID: 27079673.

60. Landoni V, Fiorino C, Cozzarini C, Sanguineti G, **Valdagni R**, Rancati T. Predicting toxicity in radiotherapy for prostate cancer. *Phys Med.* 2016Mar;32(3):521-32. doi: 10.1016/j.ejmp.2016.03.003. Epub 2016 Apr 8. Review. PubMed PMID: 27068274.

61. Palorini F, Cozzarini C, Gianolini S, Botti A, Carillo V, Iotti C, Rancati T, **Valdagni R**, Fiorino C. First application of a pixel-wise analysis on bladder dose-surface maps in prostate cancer radiotherapy. *Radiother Oncol.* 2016Apr;119(1):123-8. doi: 10.1016/j.radonc.2016.02.025. Epub 2016 Mar 15. PubMed PMID: 26993415.

62. Di Muzio NG, Fodor A, Noris Chiorda B, Broggi S, Mangili P, **Valdagni R**, Dell'Oca I, Pasetti M, Deantoni CL, Chiara A, Berardi G, Briganti A, Calandrino R, Cozzarini C, Fiorino C. Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study. *Clin Oncol (R Coll Radiol).* 2016 Aug;28(8):490-500. doi:10.1016/j.clon.2016.02.005. Epub 2016 Mar 5. PubMed PMID: 26961088.

63. Bruinsma SM, Bangma CH, Carroll PR, Leapman MS, Rannikko A, Petrides N, Weerakoon M, Bokhorst LP, Roobol MJ; Movember GAP3 consortium. Active surveillance for prostate cancer: a narrative review of clinical guidelines. *Nat Rev Urol.* 2016 Mar;13(3):151-67. doi: 10.1038/nrurol.2015.313. Epub 2016 Jan 27. Review. PubMed PMID: 26813955.

64. Palorini F, Rancati T, Cozzarini C, Improta I, Carillo V, Avuzzi B, Casanova Borca V, Botti A, Degli Esposti C, Franco P, Garibaldi E, Girelli G, Iotti C, Maggio A, Palombarini M, Pierelli A, Pignoli E, Vavassori V, **Valdagni R**, Fiorino C. Multi-variable models of large International Prostate Symptom Score worsening at the end of therapy in prostate cancer radiotherapy. *Radiother Oncol.* 2016Jan;118(1):92-8. doi: 10.1016/j.radonc.2015.11.036. Epub 2016 Jan 6. PubMed PMID: 26777123.

65. Capocaccia R, Foschi R, Zucchetto A, **Valdagni R**, Nicolai N, Maffezzini M, Gatta G. Estimates of prostate cancer burden in Italy. *Cancer Epidemiol.* 2016Feb;40:166-72. doi: 10.1016/j.canep.2015.12.004. Epub 2015 Dec 29. PubMed PMID: 26771313.

66. Bokhorst LP, Lepistö I, Kakehi Y, Bangma CH, Pickles T, **Valdagni R**, Alberts AR, Semjonow A, Strölin P, Montesino MF, Berge V, Roobol MJ, Rannikko A. Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate Cancer Research International: Active Surveillance (PRIAS) study. *BJU Int.* 2016Sep;118(3):366-71. doi: 10.1111/bju.13410. Epub 2016 Feb 12. PubMed PMID: 26765682.

67. Mosconi P, Colombo C, Satolli R, Carzaniga S; Steering Committee; Scientific Committee. Involving a Citizens' Jury in Decisions on Individual Screening for Prostate Cancer. *PLoS One.* 2016 Jan 11;11(1):e0143176. doi:10.1371/journal.pone.0143176. eCollection 2016. PubMed PMID: 26751212; PubMed Central PMCID: PMC4709131.

68. Moriconi S, Scalco E, Broggi S, Avuzzi B, **Valdagni R**, Rizzo G. High quality surface reconstruction in radiotherapy: Cross-sectional contours to 3D mesh using wavelets. *Conf Proc IEEE Eng Med Biol Soc.* 2015;2015:4222-5. doi:10.1109/EMBC.2015.7319326. PubMed PMID: 26737226.

69. Frigerio B, Benigni F, Luison E, Seregini E, Pascali C, Fracasso G, Morlino S, **Valdagni R**, Mezzanzanica D, Canevari S, Figini M. Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate-specific membrane antigen. *Immunol Lett*. 2015 Nov;168(1):105-10. doi:10.1016/j.imlet.2015.09.012. Epub 2015 Sep 25. PubMed PMID: 26404855.
70. Doldi V, Callari M, Giannoni E, D'Aiuto F, Maffezzini M, **Valdagni R**, Chiarugi P, Gandellini P, Zaffaroni N. Integrated gene and miRNA expression analysis of prostate cancer associated fibroblasts supports a prominent role for interleukin-6 in fibroblast activation. *Oncotarget*. 2015 Oct 13;6(31):31441-60. doi: 10.18632/oncotarget.5056. PubMed PMID: 26375444; PubMed Central PMCID: PMC4741617.
71. Cozzarini C, Rancati T, Carillo V, Civardi F, Garibaldi E, Franco P, Avuzzi B, Esposti CD, Girelli G, Iotti C, Palorini F, Vavassori V, **Valdagni R**, Fiorino C. Multi-variable models predicting specific patient-reported acute urinary symptoms after radiotherapy for prostate cancer: Results of a cohort study. *Radiother Oncol*. 2015 Aug;116(2):185-91. doi: 10.1016/j.radonc.2015.07.048. Epub 2015 Aug 11. PubMed PMID: 26276529.
72. Bokhorst LP, Alberts AR, Rannikko A, **Valdagni R**, Pickles T, Kakehi Y, Bangma CH, Roobol MJ; PRIAS study group. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers. *Eur Urol*. 2015 Nov;68(5):814-21. doi:10.1016/j.eururo.2015.06.012. Epub 2015 Jun 29. PubMed PMID: 26138043.
73. **Valdagni R**, Van Poppel H, Aitchison M, Albers P, Berthold D, Bossi A, Brausi M, Denis L, Drudge-Coates L, De Santis M, Feick G, Harrison C, Haustermans K, Hollywood D, Hoyer M, Hummel H, Mason M, Mirone V, Müller SC, Parker C, Saghatelyan M, Sternberg CN, Tombal B, van Muilekom E, Watson M, Wesselmann S, Wiegel T, Magnani T, Costa A. Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology. *Crit Rev Oncol Hematol*. 2015 Aug;95(2):133-43. doi: 10.1016/j.critrevonc.2015.05.014. Epub 2015 Jun 5. Review. PubMed PMID: 26092320.
74. Vasarainen H, Salman J, Salminen H, **Valdagni R**, Pickles T, Bangma C, Roobol MJ, Rannikko A. Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS). *World J Urol*. 2015 Nov;33(11):1735-40. doi: 10.1007/s00345-015-1542-3. Epub 2015 Mar 31. PubMed PMID: 25822705.
75. Jereczek-Fossa BA, Colombo R, Magnani T, Fodor C, Gerardi MA, Antognoni P, Barsacchi L, Bedini N, Bracelli S, Buffoli A, Cagna E, Catalano G, Gottardo S, Italia C, Ivaldi GB, Masciullo S, Merlotti A, Sarti E, Scorsetti M, Serafini F, Toninelli M, Vitali E, **Valdagni R**, Villa E, Zerini D, De Cobelli O, Orecchia R. Urinary bladder preservation for muscle-invasive bladder cancer: a survey among radiation oncologists of Lombardy, Italy. *Tumori*. 2015 Mar-Apr;101(2):174-8. doi:10.5301/tj.5000235. Epub 2015 Mar 5. PubMed PMID: 25744865.
76. Bellardita L, **Valdagni R**, van den Bergh R, Randsdorp H, Repetto C, Venderbos LD, Lane JA, Korfage IJ. How does active surveillance for prostate cancer affect quality of life? A systematic review. *Eur Urol*. 2015 Apr;67(4):637-45. doi:10.1016/j.eururo.2014.10.028. Epub 2014 Oct 31. Review. PubMed PMID: 25454617.
77. Bangma CH, **Valdagni R**, Carroll PR, van Poppel H, Klotz L, Hugosson J. Active surveillance for low-risk prostate cancer: developments to date. *Eur Urol*. 2015 Apr;67(4):646-8. doi: 10.1016/j.eururo.2014.11.004. Epub 2014 Nov 27. PubMed PMID: 25435266.
78. West C, Azria D, Chang-Claude J, Davidson S, Lambin P, Rosenstein B, DeRuysscher D, Talbot C, Thierens H, **Valdagni R**, Vega A, Yuille M. The REQUITE project: validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in cancer survivors. *Clin Oncol (R Coll Radiol)*. 2014 Dec;26(12):739-42. doi: 10.1016/j.clon.2014.09.008. Epub 2014 Sep 27. PubMed PMID: 25267305.
79. Voigt W, Hoellthaler J, Magnani T, Corrao V, **Valdagni R**. 'Act on oncology' as a new comprehensive approach to assess prostate cancer centres--method description and results of a pilot study. *PLoS One*. 2014 Sep 5;9(9):e106743. doi:10.1371/journal.pone.0106743. eCollection 2014. PubMed PMID: 25192213; PubMed Central PMCID: PMC4156386.
80. Gandellini P, Rancati T, **Valdagni R**, Zaffaroni N. miRNAs in tumor radiation response: bystanders or participants? *Trends Mol Med*. 2014 Sep;20(9):529-39. doi:10.1016/j.molmed.2014.07.004. Epub 2014 Aug 18. Review. PubMed PMID: 25153824.
81. Maggio A, Magli A, Rancati T, Fiorino C, Valvo F, Fellin G, Ricardi U, Munoz F, Cosentino D, Cazzaniga LF, **Valdagni R**, Vavassori V. Daily sodium butyrate enema for the prevention of radiation proctitis in prostate cancer patients undergoing radical radiation therapy: results of a multicenter randomized placebo-controlled dose-finding

phase 2 study. *Int J Radiat Oncol Biol Phys*. 2014 Jul 1;89(3):518-24. doi: 10.1016/j.ijrobp.2014.03.018. Epub 2014 May 3. PubMed PMID: 24803033.

82. Bellardita L, Villa S, **Valdagni R**. Living with untreated prostate cancer: predictors of quality of life. *Curr Opin Urol*. 2014 May;24(3):311-7. doi:10.1097/MOU.000000000000038. Review. PubMed PMID: 24637318.

83. Carillo V, Cozzarini C, Rancati T, Avuzzi B, Botti A, Borca VC, Cattari G, Civardi F, Esposti CD, Franco P, Girelli G, Maggio A, Muraglia A, Palombarini M, Pierelli A, Pignoli E, Vavassori V, Zeverino M, **Valdagni R**, Fiorino C. Relationships between bladder dose-volume/surface histograms and acute urinary toxicity after radiotherapy for prostate cancer. *Radiother Oncol*. 2014 Apr;111(1):100-5. doi: 10.1016/j.radonc.2014.02.006. Epub 2014 Mar 13. PubMed PMID: 24631144.

84. Killick E, Tymrakiewicz M, Cieza-Borrella C, Smith P, Thompson DJ, Pooley KA, Easton DF, Bancroft E, Page E, Leongamornlert D; IMPACT collaborators, Kote-Jarai Z, Eeles RA. Telomere length shows no association with BRCA1 and BRCA2 mutation status. *PLoS One*. 2014 Jan 29;9(1):e86659. doi: 10.1371/journal.pone.0086659. eCollection 2014. PubMed PMID: 24489760; PubMed Central PMCID: PMC3906069.

85. Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Mæhle L, Axcrone K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeny LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A, Skytte AB, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Blanco I, Salinas M, Cook J, Rosario DJ, Buys S, Conner T, Ausems MG, Ong KR, Hoffman J, Domchek S, Powers J, Teixeira MR, Maia S, Foulkes WD, Taherian N, Ruijs M, Helderma-van den Enden AT, Izatt L, Davidson R, Adank MA, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman GJ, Zgajnar J, Tischkowitz M, Clowes VE, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady AF, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor DJ, Copakova L, Barwell J, Giri VN, Murthy V, Nicolai N, Teo SH, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrone U, Melia J, McKinley J, Mitra AV, Moynihan C, Rennert G, Suri M, Wilson P, Killick E; IMPACT Collaborators, Moss S, Eeles RA. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. *Eur Urol*. 2014 Sep;66(3):489-99. doi: 10.1016/j.eururo.2014.01.003. Epub 2014 Jan 15. Erratum in: *Eur Urol*. 2015 Jun;67(6):e126. PubMed PMID: 24484606; PubMed Central PMCID: PMC4105321.

86. Pennati M, Lopergolo A, Profumo V, De Cesare M, Sbarra S, **Valdagni R**, Zaffaroni N, Gandellini P, Folini M. miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells. *Biochem Pharmacol*. 2014 Feb 15;87(4):579-97. doi: 10.1016/j.bcp.2013.12.009. Epub 2013 Dec 24. PubMed PMID: 24370341.

87. Fellin G, Rancati T, Fiorino C, Vavassori V, Antognoni P, Baccolini M, Bianchi C, Cagna E, Borca VC, Girelli G, Iacopino B, Maliverni G, Mauro FA, Menegotti L, Monti AF, Romani F, Stasi M, **Valdagni R**. Long term rectal function after high-dose prostate cancer radiotherapy: results from a prospective cohort study. *Radiother Oncol*. 2014 Feb;110(2):272-7. doi: 10.1016/j.radonc.2013.09.028. Epub 2013 Dec 11. PubMed PMID: 24332020.

88. Bellardita L, Rancati T, **Valdagni R**. Editorial Comment to Health-related quality of life after carbon-ion radiotherapy for prostate cancer: a 3-year prospective study. *Int J Urol*. 2014 Apr;21(4):375-6. doi: 10.1111/iju.12342. Epub 2013 Nov 13. PubMed PMID: 24224716.

89. Tombal B, Alcaraz A, James N, **Valdagni R**, Irani J. Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer? *BJU Int*. 2014 Feb;113(2):189-99. doi: 10.1111/bju.12469. Review. PubMed PMID: 24112742.

90. Procopio G, Grassi P, Testa I, Verzoni E, Torri V, Salvioni R, **Valdagni R**, de Braud F. Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. *Am J Clin Oncol*. 2015 Oct;38(5):479-82. doi: 10.1097/COC.0b013e3182a790ce. PubMed PMID: 24064757.

91. Descovich M, Carrara M, Morlino S, Pinnaduwage DS, Saltiel D, Pouliot J, Nash MB, Pignoli E, **Valdagni R**, Roach M 3rd, Gottschalk AR. Improving plan quality and consistency by standardization of dose constraints in prostate cancer patients treated with CyberKnife. *J Appl Clin Med Phys*. 2013 Sep 6;14(5):162-72. doi:10.1120/jacmp.v14i5.4333. PubMed PMID: 24036869; PubMed Central PMCID: PMC5714582.

92. Gandellini P, Giannoni E, Casamichele A, Taddei ML, Callari M, Piovon C, **Valdagni R**, Pierotti MA, Zaffaroni N, Chiarugi P. miR-205 hinders the malignant interplay between prostate cancer cells and associated fibroblasts. *Antioxid Redox Signal*. 2014 Mar 1;20(7):1045-59. doi: 10.1089/ars.2013.5292. Epub 2013 Sep 17. PubMed PMID: 23924028; PubMed Central PMCID: PMC3929333.
93. **Valdagni R**, Rancati T. Reducing rectal injury during external beam radiotherapy for prostate cancer. *Nat Rev Urol*. 2013 Jun;10(6):345-57. doi:10.1038/nrurol.2013.96. Epub 2013 May 14. Review. PubMed PMID: 23670182.
94. Maggio A, Carillo V, Cozzarini C, Perna L, Rancati T, **Valdagni R**, Gabriele P, Fiorino C. Impact of the radiotherapy technique on the correlation between dose-volume histograms of the bladder wall defined on MRI imaging and dose-volume/surface histograms in prostate cancer patients. *Phys Med Biol*. 2013 Apr 7;58(7):N115-23. doi: 10.1088/0031-9155/58/7/N115. Epub 2013 Mar 11. PubMed PMID: 23475338.
95. Bellardita L, **Valdagni R**, Rancati T. Reply from authors re: Laurence Klotz. Active surveillance, quality of life, and cancer-related anxiety. *Eur Urol* 2013;64:37-9: active surveillance: risk and protective factors for quality of life. *Eur Urol*. 2013 Jul;64(1):39-40. doi: 10.1016/j.eururo.2013.02.028. Epub 2013 Feb 26. PubMed PMID: 23465522.
96. Bellardita L, Rancati T, Alvisi MF, Villani D, Magnani T, Marengi C, Nicolai N, Procopio G, Villa S, Salvioni R, **Valdagni R**. Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance. *Eur Urol*. 2013 Jul;64(1):30-6. doi: 10.1016/j.eururo.2013.01.009. Epub 2013 Jan 21. PubMed PMID: 23357351.
97. Horwich A, Hugosson J, de Reijke T, Wiegel T, Fizazi K, Kataja V; Panel Members; European Society for Medical Oncology. Prostate cancer: ESMO Consensus Conference Guidelines 2012. *Ann Oncol*. 2013 May;24(5):1141-62. doi:10.1093/annonc/mds624. Epub 2013 Jan 9. PubMed PMID: 23303340.
98. Carillo V, Cozzarini C, Chietera A, Perna L, Gianolini S, Maggio A, Botti A, Rancati T, **Valdagni R**, Fiorino C. Correlation between surrogates of bladder dosimetry and dose-volume histograms of the bladder wall defined on MRI in prostate cancer radiotherapy. *Radiother Oncol*. 2012 Nov;105(2):180-3. doi:10.1016/j.radonc.2012.10.001. Epub 2012 Nov 22. PubMed PMID: 23182056.
99. Bul M, Zhu X, **Valdagni R**, Pickles T, Kakehi Y, Rannikko A, Bjartell A, vander Schoot DK, Cornel EB, Conti GN, Boevé ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strölin P, van Muilekom E, Schröder FH, Bangma CH, Roobol MJ. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. *Eur Urol*. 2013 Apr;63(4):597-603. doi: 10.1016/j.eururo.2012.11.005. Epub 2012 Nov 12. PubMed PMID: 23159452.
100. Rivoltini L, Marrari A, Castelli C, Villa S, **Valdagni R**. Don't run before you can walk. *Nat Rev Urol*. 2012 Oct;9(10):602. doi: 10.1038/nrurol.2012.103-c1. Epub 2012 Sep 25. PubMed PMID: 23007837.
101. Bangma CH, Bul M, van der Kwast TH, Pickles T, Korfage IJ, Hoeks CM, Steyerberg EW, Jenster G, Kattan MW, Bellardita L, Carroll PR, Denis LJ, Parker C, Roobol MJ, Emberton M, Klotz LH, Rannikko A, Kakehi Y, Lane JA, Schröder FH, Semjonow A, Trock BJ, **Valdagni R**. Active surveillance for low-risk prostate cancer. *Crit Rev Oncol Hematol*. 2013 Mar;85(3):295-302. doi:10.1016/j.critrevonc.2012.07.005. Epub 2012 Aug 9. Review. PubMed PMID: 22878262.
102. Gandellini P, Profumo V, Casamichele A, Fenderico N, Borrelli S, Petrovich G, Santilli G, Callari M, Colecchia M, Pozzi S, De Cesare M, Folini M, **Valdagni R**, Mantovani R, Zaffaroni N. miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. *Cell Death Differ*. 2012 Nov;19(11):1750-60. doi: 10.1038/cdd.2012.56. Epub 2012 May 4. PubMed PMID: 22555458; PubMed Central PMCID: PMC3469086.
103. **Valdagni R**, Vavassori V, Rancati T, Fellin G, Baccolini M, Bianchi C, Cagna E, Gabriele P, Mauro F, Menegotti L, Monti AF, Stasi M, Fiorino C. Increasing the risk of late rectal bleeding after high-dose radiotherapy for prostate cancer: the case of previous abdominal surgery. Results from a prospective trial. *Radiother Oncol*. 2012 May;103(2):252-5. doi: 10.1016/j.radonc.2012.03.012. Epub 2012 Apr 20. PubMed PMID: 22521747.
104. Magnani T, **Valdagni R**, Salvioni R, Villa S, Bellardita L, Donegani S, Nicolai N, Procopio G, Bedini N, Rancati T, Zaffaroni N. The 6-year attendance of a multidisciplinary prostate cancer clinic in Italy: incidence of management changes. *BJU Int*. 2012 Oct;110(7):998-1003. doi:10.1111/j.1464-410X.2012.10970.x. Epub 2012 Mar 8. PubMed PMID: 22404874.
105. Carillo V, Cozzarini C, Perna L, Calandra M, Gianolini S, Rancati T, Spinelli AE, Vavassori V, Villa S, **Valdagni R**, Fiorino C. Contouring variability of the penile bulb on CT images: quantitative assessment using a

generalized concordance index. *Int J Radiat Oncol Biol Phys*. 2012 Nov 1;84(3):841-6. doi:10.1016/j.ijrobp.2011.12.057. Epub 2012 Mar 6. PubMed PMID: 22401919.

106. Tomatis S, Rancati T, Fiorino C, Vavassori V, Fellin G, Cagna E, Mauro FA, Girelli G, Monti A, Baccolini M, Naldi G, Bianchi C, Menegotti L, Pasquino M, Stasi M, **Valdagni R**. Late rectal bleeding after 3D-CRT for prostate cancer: development of a neural-network-based predictive model. *Phys Med Biol*. 2012 Mar 7;57(5):1399-412. doi: 10.1088/0031-9155/57/5/1399. Epub 2012 Feb 21. PubMed PMID: 22349550.

107. Bul M, Zhu X, Rannikko A, Staerman F, **Valdagni R**, Pickles T, Bangma CH, Roobol MJ. Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. *Eur Urol*. 2012 Aug;62(2):195-200. doi: 10.1016/j.eururo.2012.02.002. Epub 2012 Feb 14. PubMed PMID: 22342775.

108. Fiorino C, Rancati T, Fellin G, Vavassori V, Cagna E, Casanova Borca V, Girelli G, Menegotti L, Monti AF, Tortoreto F, Delle Canne S, **Valdagni R**. Late fecal incontinence after high-dose radiotherapy for prostate cancer: better prediction using longitudinal definitions. *Int J Radiat Oncol Biol Phys*. 2012 May 1;83(1):38-45. doi: 10.1016/j.ijrobp.2011.06.1953. Epub 2011 Oct 8. PubMed PMID: 21985939.

109. Perna L, Cozzarini C, Maggiulli E, Fellin G, Rancati T, **Valdagni R**, Vavassori V, Villa S, Fiorino C. Inter-observer variability in contouring the penile bulb on CT images for prostate cancer treatment planning. *Radiat Oncol*. 2011 Sep 24;6:123. doi: 10.1186/1748-717X-6-123. PubMed PMID: 21943002; PubMed Central PMCID: PMC3191359.

110. **Valdagni R**. Prostate cancer units: has the time come to discuss this thorny issue and promote their establishment in Europe? *Eur Urol*. 2011 Dec;60(6):1193-6. doi: 10.1016/j.eururo.2011.08.022. Epub 2011 Aug 19. PubMed PMID: 21885184.

111. **Valdagni R**, Nahum AE, Magnani T, Italia C, Lanceni A, Montanaro P, Rancati T, Avuzzi B, Fiorino C. Long-term biochemical control of prostate cancer after standard or hyper-fractionation: evidence for different outcomes between low-intermediate and high risk patients. *Radiother Oncol*. 2011 Dec;101(3):454-9. doi: 10.1016/j.radonc.2011.07.017. Epub 2011 Aug 26. PubMed PMID: 21872954.

112. Rancati T, Fiorino C, Fellin G, Vavassori V, Cagna E, Casanova Borca V, Girelli G, Menegotti L, Monti AF, Tortoreto F, Delle Canne S, **Valdagni R**. Inclusion of clinical risk factors into NTCP modelling of late rectal toxicity after high dose radiotherapy for prostate cancer. *Radiother Oncol*. 2011 Jul;100(1):124-30. doi: 10.1016/j.radonc.2011.06.032. Epub 2011 Jul 7. PubMed PMID: 21741721.

113. Bul M, van den Bergh RC, Rannikko A, **Valdagni R**, Pickles T, Bangma CH, Roobol MJ. Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program. *Eur Urol*. 2012 Feb;61(2):370-7. doi: 10.1016/j.eururo.2011.06.027. Epub 2011 Jun 24. PubMed PMID: 21704447.

114. **Valdagni R**, Kattan MW, Rancati T, Yu C, Vavassori V, Fellin G, Cagna E, Gabriele P, Mauro FA, Baccolini M, Bianchi C, Menegotti L, Monti AF, Stasi M, Giganti MO, Fiorino C. Is it time to tailor the prediction of radio-induced toxicity in prostate cancer patients? Building the first set of nomograms for late rectal syndrome. *Int J Radiat Oncol Biol Phys*. 2012 Apr 1;82(5):1957-66. doi: 10.1016/j.ijrobp.2011.03.028. Epub 2011 Jun 2. PubMed PMID: 21640511.

115. Bellardita L, Donegani S, Spatuzzi AL, **Valdagni R**. Multidisciplinary Versus One-on-One Setting: A Qualitative Study of Clinicians' Perceptions of Their Relationship With Patients With Prostate Cancer. *J Oncol Pract*. 2011 Jan;7(1):e1-5. doi: 10.1200/JOP.2010.000020. PubMed PMID: 21532797; PubMed Central PMCID: PMC3014517.

116. **Valdagni R**, Albers P, Bangma C, Drudge-Coates L, Magnani T, Moynihan C, Parker C, Redmond K, Sternberg CN, Denis L, Costa A. The requirements of a specialist Prostate Cancer Unit: a discussion paper from the European School of Oncology. *Eur J Cancer*. 2011 Jan;47(1):1-7. doi: 10.1016/j.ejca.2010.10.029. Epub 2010 Dec 1. PubMed PMID: 21126868.

117. Procopio G, Guadalupi V, Giganti MO, Mariani L, Salvioni R, Nicolai N, Capone F, **Valdagni R**, Bajetta E. Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. *BJU Int*. 2011 Jul;108(2):223-7. doi: 10.1111/j.1464-410X.2010.09825.x. Epub 2010 Nov 15. PubMed PMID: 21078047.

118. Folini M, Gandellini P, Longoni N, Profumo V, Callari M, Pennati M, Colecchia M, Supino R, Veneroni S, Salvioni R, **Valdagni R**, Daidone MG, Zaffaroni N. miR-21: an oncomir on strike in prostate cancer. *Mol Cancer*. 2010 Jan 21;9:12. doi: 10.1186/1476-4598-9-12. PubMed PMID: 20092645; PubMed Central PMCID:PMC2823650.
119. Fellin G, Fiorino C, Rancati T, Vavassori V, Baccolini M, Bianchi C, Cagna E, Gabriele P, Mauro F, Menegotti L, Monti AF, Stasi M, **Valdagni R**. Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: results of a large multicenter observational study. *Radiother Oncol*. 2009 Nov;93(2):197-202. doi: 10.1016/j.radonc.2009.09.004. Epub 2009 Oct 12. PubMed PMID: 19828205.
120. van den Bergh RC, Vasarainen H, van der Poel HG, Vis-Maters JJ, Rietbergen JB, Pickles T, Cornel EB, **Valdagni R**, Jaspars JJ, van der Hoeven J, Staerman F, Oomens EH, Rannikko A, Roemeling S, Steyerberg EW, Roobol MJ, Schröder FH, Bangma CH. Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study. *BJU Int*. 2010 Apr;105(7):956-62. doi: 10.1111/j.1464-410X.2009.08887.x. Epub 2009 Oct 8. PubMed PMID: 19817747.
121. Fiorino C, **Valdagni R**, Rancati T, Sanguineti G. Dose-volume effects for normal tissues in external radiotherapy: pelvis. *Radiother Oncol*. 2009 Nov;93(2):153-67. doi: 10.1016/j.radonc.2009.08.004. Epub 2009 Sep 16. Review. PubMed PMID: 19765845.
122. Pilla L, Rivoltini L, Patuzzo R, Marrari A, **Valdagni R**, Parmiani G. Multi-peptide vaccination in cancer patients. *Expert Opin Biol Ther*. 2009 Aug;9(8):1043-55. doi: 10.1517/14712590903085109. Review. PubMed PMID: 19591629.
123. **Valdagni R**, Scardino PT, Denis L. The 2008 European School of Oncology inside track conference, "predictive modeling in prostate cancer". *Cancer*. 2009 Jul 1;115(13 Suppl):3035-8. doi: 10.1002/cncr.24342. PubMed PMID: 19544554.
124. **Valdagni R**, Rancati T, Fiorino C. Predictive models of toxicity with external radiotherapy for prostate cancer: clinical issues. *Cancer*. 2009 Jul 1;115(13 Suppl):3141-9. doi: 10.1002/cncr.24356. Review. PubMed PMID: 19544543.
125. Fiorino C, Rancati T, **Valdagni R**. Predictive models of toxicity in external radiotherapy: dosimetric issues. *Cancer*. 2009 Jul 1;115(13 Suppl):3135-40. doi: 10.1002/cncr.24354. Review. PubMed PMID: 19544542.
126. Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, Salvioni R, Supino R, Moretti R, Limonta P, **Valdagni R**, Daidone MG, Zaffaroni N. miR-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase C epsilon. *Cancer Res*. 2009 Mar 15;69(6):2287-95. doi: 10.1158/0008-5472.CAN-08-2894. Epub 2009 Feb 24. PubMed PMID: 19244118.
127. Gatta G, Zigon G, Buemi A, Coebergh JW, Colonna M, Contiero P, Denis L, Grosclaude P, Guizard AV, Sanchez-Perez MJ, Plesko I, Ondrusova M, Rachtan J, **Valdagni R**, Velten M, Vercelli M, Berrino F. Prostate cancer treatment in Europe at the end of 1990s. *Acta Oncol*. 2009;48(6):867-73. doi: 10.1080/02841860902719174. Erratum in: *Acta Oncol*. 2013 May;52(4):882. PubMed PMID: 19235570.
128. **Valdagni R**, Rancati T, Ghilotti M, Cozzarini C, Vavassori V, Fellin G, Fiorino C, Girelli G, Barra S, Zaffaroni N, Pierotti MA, Gariboldi M. To bleed or not to bleed. A prediction based on individual gene profiling combined with dose-volume histogram shapes in prostate cancer patients undergoing three-dimensional conformal radiation therapy. *Int J Radiat Oncol Biol Phys*. 2009 Aug 1;74(5):1431-40. doi: 10.1016/j.ijrobp.2008.10.021. Epub 2009 Feb 11. PubMed PMID: 19211196.
129. Di Muzio N, Fiorino C, Cozzarini C, Alongi F, Broggi S, Mangili P, Guazzoni G, **Valdagni R**, Calandrino R, Fazio F. Phase I-II study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer. *Int J Radiat Oncol Biol Phys*. 2009 Jun 1;74(2):392-8. doi: 10.1016/j.ijrobp.2008.08.038. Epub 2008 Dec 4. PubMed PMID: 19056184.
130. Iero M, Filipazzi P, Castelli C, Belli F, **Valdagni R**, Parmiani G, Patuzzo R, Santinami M, Rivoltini L. Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity? *Cancer Immunol Immunother*. 2009 Jul;58(7):1159-67. doi: 10.1007/s00262-008-0610-6. Epub 2008 Nov 8. PubMed PMID: 18998128.
131. **Valdagni R**, Scardino PT, Denis L, Kattan MW. Predictive modeling in prostate cancer: a conference summary. *Eur Urol*. 2009 Feb;55(2):300-2. doi: 10.1016/j.eururo.2008.09.004. Epub 2008 Sep 17. PubMed PMID: 18834662.

132. Begnozzi L, Benassi M, Bertanelli M, Bonini A, Cionini L, Conte L, Fiorino C, Gabriele P, Gardani G, Giani A, Magri S, Morelli M, Morrica B, Olmi P, Orecchia R, Penduzzo G, Raffaele L, Rosi A, Tabocchini MA, **Valdagni R**, Viti V. Quality assurance of 3D-CRT: indications and difficulties in their applications. *Crit Rev Oncol Hematol*. 2009 Apr;70(1):24-38. doi:10.1016/j.critrevonc.2008.07.016. Epub 2008 Sep 2. Review. PubMed PMID: 18768328.
133. Aristei C, Amichetti M, Ciocca M, Nardone L, Bertoni F, Vidali C; Italian Society of Radiation Oncology. Radiotherapy in Italy after conservative treatment of early breast cancer. A survey by the Italian Society of Radiation Oncology (AIRO). *Tumori*. 2008 May-Jun;94(3):333-41. PubMed PMID: 18705400.
134. Fiorino C, Alongi F, Broggi S, Cattaneo GM, Cozzarini C, Di Muzio N, Maggiulli E, Mangili P, Perna L, **Valdagni R**, Fazio F, Calandrino R. Physics aspects of prostate tomotherapy: planning optimization and image-guidance issues. *Acta Oncol*. 2008;47(7):1309-16. doi: 10.1080/02841860802266755. PubMed PMID: 18686050.
135. Cozzarini C, Fiorino C, Di Muzio N, **Valdagni R**, Salonia A, Alongi F, Broggi S, Guazzoni G, Montorsi F, Rigatti P, Calandrino R, Fazio F. Hypofractionated adjuvant radiotherapy with helical tomotherapy after radical prostatectomy: planning data and toxicity results of a Phase I-II study. *Radiother Oncol*. 2008 Jul;88(1):26-33. doi: 10.1016/j.radonc.2008.03.021. Epub 2008 Apr 30. PubMed PMID: 18452523.
136. Fiorino C, Di Muzio N, Broggi S, Cozzarini C, Maggiulli E, Alongi F, **Valdagni R**, Fazio F, Calandrino R. Evidence of limited motion of the prostate by carefully emptying the rectum as assessed by daily MVCT image guidance with helical tomotherapy. *Int J Radiat Oncol Biol Phys*. 2008 Jun 1;71(2):611-7. doi:10.1016/j.ijrobp.2008.01.048. Epub 2008 Apr 18. PubMed PMID: 18374511.
137. **Valdagni R**, Rancati T, Fiorino C, Fellin G, Magli A, Baccolini M, Bianchi C, Cagna E, Greco C, Mauro FA, Monti AF, Munoz F, Stasi M, Franzone P, Vavassori V. Development of a set of nomograms to predict acute lower gastrointestinal toxicity for prostate cancer 3D-CRT. *Int J Radiat Oncol Biol Phys*. 2008 Jul 15;71(4):1065-73. doi: 10.1016/j.ijrobp.2007.11.037. Epub 2008 Jan 30. PubMed PMID: 18234449.
138. Inghelmann R, Grande E, Francisci S, Verdecchia A, Micheli A, Baili P, Gatta G, Capocaccia R, **Valdagni R**, De Angelis R. Regional estimates of prostate cancer burden in Italy. *Tumori*. 2007 Jul-Aug;93(4):380-6. PubMed PMID: 17899869.
139. Fiorino C, Fellin G, Rancati T, Vavassori V, Bianchi C, Borca VC, Girelli G, Mapelli M, Menegotti L, Nava S, **Valdagni R**. Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: preliminary results of a multicenter prospective study. *Int J Radiat Oncol Biol Phys*. 2008 Mar 15;70(4):1130-7. Epub 2007 Sep 19. PubMed PMID: 17881142.
140. Vavassori V, Fiorino C, Rancati T, Magli A, Fellin G, Baccolini M, Bianchi C, Cagna E, Mauro FA, Monti AF, Munoz F, Stasi M, Franzone P, **Valdagni R**. Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study. *Int J Radiat Oncol Biol Phys*. 2007 Apr 1;67(5):1401-10. Epub 2007 Jan 22. PubMed PMID: 17241754.
141. Doherty R, Lubinski J, Manguoglu E, Luleci G, Christie M, Craven P, Bancroft E, Mitra A, Morgan S, Eeles R; IMPACT steering committee and collaborators. Short report. The AIDIT and IMPACT conference 2006: Outcomes and future directions. *Hered Cancer Clin Pract*. 2007 Mar 15;5(1):53-5. doi: 10.1186/1897-4287-5-1-53. PubMed PMID: 19723350; PubMed Central PMCID: PMC2736762.
142. Marrari A, Iero M, Pilla L, Villa S, Salvioni R, **Valdagni R**, Parmiani G, Rivoltini L. Vaccination therapy in prostate cancer. *Cancer Immunol Immunother*. 2007 Apr;56(4):429-45. Epub 2006 Oct 10. Review. PubMed PMID: 17031640.
143. Stasi M, Munoz F, Fiorino C, Pasquino M, Baiotto B, Marini P, Malinverni G, **Valdagni R**, Gabriele P. Emptying the rectum before treatment delivery limits the variations of rectal dose - volume parameters during 3DCRT of prostate cancer. *Radiother Oncol*. 2006 Sep;80(3):363-70. Epub 2006 Sep 7. PubMed PMID: 16959344.
144. Bracarda S, de Cobelli O, Greco C, Prayer-Galetti T, **Valdagni R**, Gatta G, deBraud F, Bartsch G. Cancer of the prostate. *Crit Rev Oncol Hematol*. 2005 Dec;56(3):379-96. Review. PubMed PMID: 16310371.
145. **Valdagni R**, Salvioni R, Nicolai N, Villa S, Bedini N, Bajetta E, Procopio G, Donegani S, Bosisio M. In regard to Kagan: "The multidisciplinary clinic" (*Int J Radiat Oncol Biol Phys* 2005;61:967-968). *Int J Radiat Oncol Biol Phys*. 2005 Sep 1;63(1):309-10. PubMed PMID: 16111603.

146. Malinverni G, Greco C, Bianchi P, Busutti L, Cagna E, Cozzarini C, Del Duca M, Franzone P, Frezza G, Gabriele P, Genovesi D, Girelli GF, Italia C, Mandoliti G, Mauro F, Nava S, Pratisoli S, Saracino MB, Squillace L, Signor M, Tagliagambe A, Vavassori V, Villa S, Zini G, **Valdagni R**. Italian survey in postoperative radiation therapy for prostate carcinoma by the AIRO National Working Group on Prostate Radiotherapy: definitive results. *Tumori*. 2005 Mar-Apr;91(2):156-62. PubMed PMID: 15948544.
147. **Valdagni R**, Italia C, Montanaro P, Lanceni A, Lattuada P, Magnani T, Fiorino C, Nahum A. Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy. *Radiother Oncol*. 2005 Apr;75(1):74-82. Epub 2005 Apr 18. PubMed PMID: 15878104.
148. Fiorino C, Sanguineti G, **Valdagni R**. Fractionation and late rectal toxicity: no reliable estimates of alpha/beta value for rectum can be derived from studies where different volumes of rectum are irradiated at different dose levels: in regard to Brenner (*Int J Radiat Oncol Biol Phys* 2004;60:1013-1015.). *Int J Radiat Oncol Biol Phys*. 2005 May 1;62(1):289-90; author reply 290-1. PubMed PMID: 15850935.
149. Rancati T, Fiorino C, Gagliardi G, Cattaneo GM, Sanguineti G, Borca VC, Cozzarini C, Fellin G, Foppiano F, Girelli G, Menegotti L, Piazzolla A, Vavassori V, **Valdagni R**. Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101). *Radiother Oncol*. 2004 Oct;73(1):21-32. PubMed PMID: 15465142.
150. Fiorino C, Sanguineti G, Cozzarini C, Fellin G, Foppiano F, Menegotti L, Piazzolla A, Vavassori V, **Valdagni R**. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. *Int J Radiat Oncol Biol Phys*. 2003 Nov 15;57(4):953-62. PubMed PMID: 14575825.
151. Foppiano F, Fiorino C, Frezza G, Greco C, **Valdagni R**; AIRO National Working Group on Prostate Radiotherapy. The impact of contouring uncertainty on rectal 3D dose-volume data: results of a dummy run in a multicenter trial (AIROPROS01-02). *Int J Radiat Oncol Biol Phys*. 2003 Oct 1;57(2):573-9. PubMed PMID: 12957271.
152. de Braud F, Khayat D, Kroon BB, **Valdagni R**, Bruzzi P, Cascinelli N. Malignant melanoma. *Crit Rev Oncol Hematol*. 2003 Jul;47(1):35-63. Review. PubMed PMID: 12853098.
153. **Valdagni R**, Zelefsky MJ. [Hormonal therapy associated with radiotherapy of advanced carcinoma of the prostate. Comment on the study and interview with Michel Bolla]. *Recenti Prog Med*. 2001 Feb;92(2):130-2. Italian. PubMed PMID: 11294105.
154. Amichetti M, Zurlo A, Cristoforetti L, **Valdagni R**. Prognostic significance of cervical lymph nodes density evaluated by contrasted computer tomography in head and neck squamous cell carcinoma treated with hyperthermia and radiotherapy. *Int J Hyperthermia*. 2000 Nov-Dec;16(6):539-47. PubMed PMID: 11129264.
155. Amichetti M, Caffo O, Richetti A, Zini G, Rigon A, Antonello M, Roncadin M, Coghetto F, **Valdagni R**, Fasan S, Maluta S, Di Marco A, Neri S, Vidali C, Panizzoni G, Aristei C. Subclinical ductal carcinoma in situ of the breast: treatment with conservative surgery and radiotherapy. *Tumori*. 1999 Nov-Dec;85(6):488-93. PubMed PMID: 10774571.
156. Amichetti M, Romano M, Cristoforetti L, **Valdagni R**. Hyperthermia and radiotherapy for inoperable squamous cell carcinoma metastatic to cervical lymph nodes from an unknown primary site. *Int J Hyperthermia*. 2000 Jan-Feb;16(1):85-93. PubMed PMID: 10669319.
157. **Valdagni R**, Amichetti M, Ciocca M. Patterns of radiotherapy for early breast cancer in Northern Italy compared with European and national standards. *Radiother Oncol*. 1999 Apr;51(1):79-85. PubMed PMID: 10386720.
158. **Valdagni R**, Bertoni F, Bossi A, Caraffini B, Corbella F, Italia C, Källi M, Leoni M, Nava S, Sarti E, Vavassori V, Villa S. Minimal requirements in prostate cancer irradiation: a consensus document by the AIRO Lombardia Cooperative Group. *Tumori*. 1999 Mar-Apr;85(2):143-8. Review. PubMed PMID: 10363084.
159. Italia C, Fiorino C, Ciocca M, Cattaneo GM, Montanaro P, Bolognesi A, Lanceni A, Reni M, Bonini A, Modugno A, Calandrino R, **Valdagni R**. Quality control by portal film analysis in radiotherapy for prostate cancer: a comparison between two different institutions and treatment techniques. *Tumori*. 1998 Nov-Dec;84(6):640-8. PubMed PMID: 10080668.

160. **Valdagni R.** Altered fractionation in radiotherapy. *Tumori*. 1998Mar-Apr;84(2):155-9. Review. PubMed PMID: 9620239.
161. deCataldo F, Baudo F, Ottonelli C, Italia C, **Valdagni R.** Complete regression of a suprasellar secondary mass in a patient with low-grade non-Hodgkin's lymphoma (NHL) treated with 2-chlorodeoxyadenosine (CdA). *Am J Hematol*. 1998Mar;57(3):258-9. PubMed PMID: 9495381.
162. Amichetti M, Romano M, Busana L, Bolner A, Fellin G, Pani G, Tomio L, **Valdagni R.** Hyperfractionated radiation in combination with local hyperthermia in the treatment of advanced squamous cell carcinoma of the head and neck: a phase-II study. *Radiother Oncol*. 1997 Nov;45(2):155-8. PubMed PMID: 9424006.
163. Amichetti M, Caffo O, Richetti A, Zini G, Rigon A, Antonello M, Arcicasa M, Coghetto F, **Valdagni R,** Maluta S, Di Marco A. Ten-year results of treatment of ductal carcinoma in situ (DCIS) of the breast with conservative surgery and radiotherapy. *Eur J Cancer*. 1997 Sep;33(10):1559-65. PubMed PMID: 9389915.
164. **Valdagni R,** Italia C, Montanaro P, Ciocca M, Morandi G, Salvadori B. Clinical target volume localization using conventional methods (anatomy and palpation) and ultrasonography in early breast cancer post-operative external irradiation. *Radiother Oncol*. 1997 Mar;42(3):231-7. PubMed PMID: 9155071.
165. **Valdagni R,** Ciocca M, Italia C, Montanaro P, Lanceni A, Modugno A. [Clinical and methodological aspects of quality assurance in external radiotherapy: optimization of radiotherapy in early cancer of the breast]. *Radiol Med*. 1996 Oct;92(4):462-9. Review. Italian. PubMed PMID: 9045250.
166. Amichetti M, Graiff C, Romano M, Bolner A, Busana L, Fellin G, Pani G, **Valdagni R.** [Hyperthermia and palliative radiotherapy for sarcoma]. *Radiol Med*. 1996 Jun;91(6):796-8. Italian. PubMed PMID: 8830368.
167. **Valdagni R,** Arcangeli G. Past and present of radiation oncology in Italy. *Int J Radiat Oncol Biol Phys*. 1996 Jun 1;35(3):609-14. PubMed PMID: 8655387.
168. **Valdagni R,** Italia C, Montanaro P, Ciocca M. Quality assurance in early breast cancer treatment: clinical aspects of postoperative, external, whole breast irradiation. *Recent Results Cancer Res*. 1996;140:251-61. Review. PubMed PMID: 8787067.
169. Gabriele P, Amichetti M, Orecchia R, **Valdagni R.** Hyperthermia and radiation therapy for inoperable or recurrent parotid carcinoma. A phase I/II study. *Cancer*. 1995 Feb 15;75(4):908-13. PubMed PMID: 7842410.
170. Palazzi M, **Valdagni R,** Poli M, Buffoli A, Leoni M, Vavassori V, Di Lorenzoli, Corbella F, Nava S, Cazzaniga LF, et al. The role of radiotherapy in the treatment of stage III non-small cell lung cancer: a survey of clinical practices in Lombardy, Italy, by the Airo*-Lombardia Cooperative Group. *Tumori*. 1994 Aug 31;80(4):286-9. PubMed PMID: 7974800.
171. **Valdagni R,** Amichetti M. Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymph nodes in stage IV head and neck patients. *Int J Radiat Oncol Biol Phys*. 1994 Jan 1;28(1):163-9. PubMed PMID: 8270437.
172. Amichetti M, Graiff C, Fellin G, Pani G, Bolner A, Maluta S, **Valdagni R.** Cisplatin, hyperthermia, and radiation (trimodal therapy) in patients with locally advanced head and neck tumors: a phase I-II study. *Int J Radiat Oncol Biol Phys*. 1993 Aug 1;26(5):801-7. PubMed PMID: 8344849.
173. Scielzo G, Ciocca M, Zonca G, Maggi S, Ascione B, Grillo Ruggieri F, **Valdagni R,** Sverzellati PE, Spiga G, Miolo L, et al. [Comparison of acceptance tests of 5 linear electron accelerators for radiotherapy]. *Radiol Med*. 1992 Jun;83(6):804-9. Italian. PubMed PMID: 1502363.
174. **Valdagni R,** Ciocca M, Busana L, Modugno A, Italia C. Beam modifying devices in the treatment of early breast cancer: 3-D stepped compensating technique. *Radiother Oncol*. 1992 Mar;23(3):192-5. PubMed PMID: 1574598.
175. Bagshaw MA, Kaplan ID, **Valdagni R,** Cox RS. Radiation treatment of prostate bone metastases and the biological considerations. *Adv Exp Med Biol*. 1992;324:255-68. Review. PubMed PMID: 1283500.
176. **Valdagni R,** Italia C. Early breast cancer irradiation after conservative surgery: quality control by portal localization films. *Radiother Oncol*. 1991 Dec;22(4):311-3. PubMed PMID: 1792327.

177. Ciocca M, Landoni L, Italia C, Montanaro P, Canesi P, **Valdagni R**. Quality control in the conservative treatment of breast cancer: patient dosimetry using silicon detectors. *Radiother Oncol*. 1991 Dec;22(4):304-7. Review. PubMed PMID:1792325.
178. **Valdagni R**. The definition of local control. Response to Parsons. *Int J Radiat Oncol Biol Phys*. 1991 Jun;20(6):1382. PubMed PMID: 2045314.
179. **Valdagni R**. The International Consensus Meeting on Hyperthermia. *Am J Clin Oncol*. 1991 Jun;14(3):267-9. Review. PubMed PMID: 2031515.
180. Amichetti M, **Valdagni R**, Graiff C, Valentini A. Local-regional recurrences of breast cancer: treatment with radiation therapy and local microwave hyperthermia. *Am J Clin Oncol*. 1991 Feb;14(1):60-5. PubMed PMID: 1987742.
181. **Valdagni R**, Ciocca M, Italia C, Fantin PL, Landoni L, Canesi P. [Personalized low-melting alloy shield for high-energy electrons in the treatment of superficial neoplasms of critical or esthetically important regions]. *Radiol Med*. 1990 Oct;80(4 Suppl 1):46-51. Italian. PubMed PMID: 2251418.
182. **Valdagni R**. International Consensus Meeting on Hyperthermia: Final report. *Int J Hyperthermia*. 1990 Sep-Oct;6(5):839-77; discussion 879-80. Review. PubMed PMID: 2250113.
183. Pontalti R, Cristoforetti L, **Valdagni R**, Antolini R. Absorption rate density (ARD) computation in microwave hyperthermia by the finite-difference time-domain method. *Phys Med Biol*. 1990 Jul;35(7):891-904. PubMed PMID: 2385621.
184. Kaplan ID, **Valdagni R**, Cox RS, Bagshaw MA. Reduction of spinal metastases after preemptive irradiation in prostatic cancer. *Int J Radiat Oncol Biol Phys*. 1990 May;18(5):1019-25. PubMed PMID: 2347712.
185. **Valdagni R**, Liu FF. Evaluating radiation in combination with hyperthermia trials: the importance of clinical and technical parameters. *Tumori*. 1990 Apr;76(2):205-11. Review. PubMed PMID: 2184549.
186. **Valdagni R**, Amichetti M. Radiation therapy of carotid body tumors. *Am J Clin Oncol*. 1990 Feb;13(1):45-8. Review. PubMed PMID: 2154923.
187. **Valdagni R**, Liu FF, Kapp DS. Important prognostic factors influencing outcome of combined radiation and hyperthermia. *Int J Radiat Oncol Biol Phys*. 1988 Oct;15(4):959-72. Review. PubMed PMID: 3053539.
188. **Valdagni R**, Amichetti M, Cristoforetti L. Intracavitary hyperthermia: construction and heat patterns of individualized vaginal prototype applicators. *Int J Hyperthermia*. 1988 Sep-Oct;4(5):457-66. PubMed PMID: 2455758.
189. **Valdagni R**, Amichetti M, Pani G. Radical radiation alone versus radical radiation plus microwave hyperthermia for N3 (TNM-UICC) neck nodes: a prospective randomized clinical trial. *Int J Radiat Oncol Biol Phys*. 1988 Jul;15(1):13-24. PubMed PMID: 3292487.
190. **Valdagni R**. Two versus six hyperthermia treatments in combination with radical irradiation for fixed metastatic neck nodes: progress report. *Recent Results Cancer Res*. 1988;107:123-8. PubMed PMID: 3131852.
191. **Valdagni R**, Amichetti M. Clinical hyperthermia: five year's experience. *Strahlenther Onkol*. 1987 Jul;163(7):443-5. PubMed PMID: 3303391.
192. Samulski TV, Fessenden P, **Valdagni R**, Kapp DS. Correlations of thermal washout rate, steady state temperatures, and tissue type in deep seated recurrent or metastatic tumors. *Int J Radiat Oncol Biol Phys*. 1987 Jun;13(6):907-16. PubMed PMID: 3583862.
193. Amichetti M, Piffer S, **Valdagni R**, Ambrosini G, Piazza M. Peripheral DTIC neurotoxicity: a case report. *Cancer Chemother Pharmacol*. 1987;19(1):87-8. PubMed PMID: 3028665.
194. Amichetti M, Bolner A, Busana L, Fellin G, Pani G, Piffer S, **Valdagni R**, Ambrosini G. Neoadjuvant chemotherapy with vincristine, bleomycin and methotrexate combined with radiotherapy in advanced head and neck squamous cell carcinoma. *Tumori*. 1986 Jun 30;72(3):301-6. PubMed PMID: 2426850.

195. **Valdagni R**, Kapp DS, Valdagni C. N3 (TNM-UICC) metastatic neck nodes managed by combined radiation therapy and hyperthermia: clinical results and analysis of treatment parameters. *Int J Hyperthermia*. 1986 Apr-Jun;2(2):189-200. PubMed PMID:2432135.
196. Piscioli F, Pusioli T, Urbani F, **Valdagni R**, Luciani L, Cristofolini M. [Possibilities and limitations of aspiration cytology in the diagnosis and staging of cutaneous tumors]. *G Ital Dermatol Venereol*. 1986 Mar-Apr;121(2):111-6. Italian. PubMed PMID: 3710528.
197. Fellin G, Bolner A, Busana L, Ambrosini G, **Valdagni R**, Piffer S, Amichetti M, Pani G, Valdagni C. [Radiotherapy in the treatment of malignant nasosinus neoplasms. The experience of the Trento Cancer Center]. *Minerva Stomatol*. 1986 Mar;35(3):197-200. Italian. PubMed PMID: 3457255.
198. Leonardi E, Dalri P, Pusioli T, **Valdagni R**, Piscioli F. Spindle-cell squamous carcinoma of head and neck region: a clinicopathologic and immunohistochemical study of eight cases. *ORL J Otorhinolaryngol Relat Spec*. 1986;48(5):275-81. PubMed PMID: 2431373.
199. **Valdagni R**, Amichetti M, Dell'Orsola G. Local microwave hyperthermia in cancer therapy. Preliminary report. *Tumori*. 1982 Jun 30;68(3):247-51. PubMed PMID: 7135490.